Bristol Myers Squibb Company $BMY Stake Cut by Rockland Trust Co.

Rockland Trust Co. cut its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 5.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 173,075 shares of the biopharmaceutical company’s stock after selling 10,127 shares during the quarter. Rockland Trust Co.’s holdings in Bristol Myers Squibb were worth $7,806,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. CVA Family Office LLC increased its stake in shares of Bristol Myers Squibb by 2.6% in the third quarter. CVA Family Office LLC now owns 8,959 shares of the biopharmaceutical company’s stock worth $404,000 after acquiring an additional 223 shares during the last quarter. Mccarter Private Wealth Services LLC increased its position in Bristol Myers Squibb by 5.0% in the 3rd quarter. Mccarter Private Wealth Services LLC now owns 4,931 shares of the biopharmaceutical company’s stock worth $222,000 after purchasing an additional 235 shares during the last quarter. Creative Financial Designs Inc. ADV raised its stake in shares of Bristol Myers Squibb by 26.7% during the 2nd quarter. Creative Financial Designs Inc. ADV now owns 1,123 shares of the biopharmaceutical company’s stock worth $52,000 after purchasing an additional 237 shares in the last quarter. Center for Financial Planning Inc. lifted its holdings in shares of Bristol Myers Squibb by 15.9% during the 2nd quarter. Center for Financial Planning Inc. now owns 1,869 shares of the biopharmaceutical company’s stock valued at $87,000 after buying an additional 256 shares during the last quarter. Finally, Tilson Financial Group Inc. grew its stake in shares of Bristol Myers Squibb by 4.2% in the 3rd quarter. Tilson Financial Group Inc. now owns 6,445 shares of the biopharmaceutical company’s stock valued at $291,000 after buying an additional 259 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Down 2.0%

Bristol Myers Squibb stock opened at $60.75 on Tuesday. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $63.33. The firm has a fifty day moving average price of $54.57 and a two-hundred day moving average price of $49.12. The firm has a market cap of $123.67 billion, a price-to-earnings ratio of 17.61, a P/E/G ratio of 0.19 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 70.30%. The business had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same period in the prior year, the business posted $1.67 earnings per share. The company’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd were paid a $0.63 dividend. The ex-dividend date was Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio is 73.04%.

Analysts Set New Price Targets

BMY has been the topic of several recent research reports. Citigroup raised their price objective on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research report on Friday. Bank of America upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their price target for the company from $52.00 to $61.00 in a report on Monday, December 15th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Piper Sandler reissued an “overweight” rating and set a $66.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a research report on Wednesday, January 28th. Finally, Truist Financial set a $65.00 price target on Bristol Myers Squibb in a research report on Wednesday, December 3rd. Eight research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $59.20.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.